My interest in gene therapy began during my Ph.D. with Pr. Nicolas Levy (University La Timone Medical School Marseille, France). I initiated a highly translational project encompassing innovative RNA-based adeno-associated viral vector (AAV) gene therapy approaches for limb-girdle muscular dystrophy. In 2011, I accepted a postdoctoral position in Dr. Flanigan's lab at NCH working on gene therapy for Duchenne Muscular Dystrophy (DMD). My work led to the identification of a novel internal ribosome entry site (IRES) within the DMD gene. Based on these exciting findings, we developed a therapeutic approach using vectorized exon skipping (VES). Since July 2016, my lab has pursued three major areas of research: 1.VES gene therapy for DMD; 2.Development of VES gene therapy for Myotonic Dystrophy type 1; 3.Developing gene therapy for novel neurological diseases (SCN2A and IRF2BPL mutation related diseases).
My interest in gene therapy began during my Ph.D. with Pr. Nicolas Levy (University La Timone Medical School Marseille, France). I initiated a highly translational project encompassing innovative RNA-based adeno-associated viral vector (AAV) gene therapy approaches for limb-girdle muscular dystrophy. In 2011, I accepted a postdoctoral position in Dr. Flanigan's lab at NCH working on gene therapy for Duchenne Muscular Dystrophy (DMD). My work led to the identification of a novel internal ribosome entry site (IRES) within the DMD gene. Based on these exciting findings, we developed a therapeutic approach using vectorized exon skipping (VES). Since July 2016, my lab has pursued three major areas of research: 1.VES gene therapy for DMD; 2.Development of VES gene therapy for Myotonic Dystrophy type 1; 3.Developing gene therapy for novel neurological diseases (SCN2A and IRF2BPL mutation related diseases).